Keyphrases
Pembrolizumab
100%
Metastatic Urothelial Carcinoma
100%
Lymph Node Dissection
100%
Overall Survival
62%
Primary Tumor Resection
25%
Liver Metastasis
12%
Multivariate Analysis
12%
Multivariate Cox Regression Analysis
12%
Japanese Population
12%
No Significant Difference
12%
After Surgery
12%
Metastasis
12%
Non-associated
12%
Urothelial Carcinoma
12%
Neutrophil-to-lymphocyte Ratio
12%
Overall Response Rate
12%
Hemoglobin
12%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
12%
Radical Surgery
12%
Performance Status 2
12%
Recurrent Lesions
12%
Medicine and Dentistry
Transitional Cell Carcinoma
100%
Pembrolizumab
100%
Retroperitoneal Lymph Node Dissection
100%
Overall Survival
62%
Primary Tumor
25%
Cancer Surgery
25%
Proportional Hazards Model
12%
Liver Metastasis
12%
Multivariate Analysis
12%
Cohort Analysis
12%
Metastatic Carcinoma
12%
Retrospective Study
12%
Oncology
12%
Radical Surgery
12%
Lymphocyte
12%
Neutrophil
12%